Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.

Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda

Open access

Abstract

BACKGROUND: Adherence to and completion of tuberculosis (TB) treatment remain problematic in many high-burden countries. 99DOTS is a low-cost digital adherence technology that could increase TB treatment completion. METHODS AND FINDINGS: We conducted a pragmatic stepped-wedge cluster-randomized trial including all adults treated for drug-susceptible pulmonary TB at 18 health facilities across Uganda over 8 months (1 December 2018-31 July 2019). Facilities were randomized to switch from routine (control period) to 99DOTS-based (intervention period) TB treatment supervision in consecutive months. Patients were allocated to the control or intervention period based on which facility they attended and their treatment start date. Health facility staff and patients were not blinded to the intervention. The primary outcome was TB treatment completion. Due to the pragmatic nature of the trial, the primary analysis was done according to intention-to-treat (ITT) and per protocol (PP) principles. This trial is registered with the Pan African Clinical Trials Registry (PACTR201808609844917). Of 1,913 eligible patients at the 18 health facilities (1,022 and 891 during the control and intervention periods, respectively), 38.0% were women, mean (SD) age was 39.4 (14.4) years, 46.8% were HIV-infected, and most (91.4%) had newly diagnosed TB. In total, 463 (52.0%) patients were enrolled on 99DOTS during the intervention period. In the ITT analysis, the odds of treatment success were similar in the intervention and control periods (adjusted odds ratio [aOR] 1.04, 95% CI 0.68-1.58, p = 0.87). The odds of treatment success did not increase in the intervention period for either men (aOR 1.24, 95% CI 0.73-2.10) or women (aOR 0.67, 95% CI 0.35-1.29), or for either patients with HIV infection (aOR 1.51, 95% CI 0.81-2.85) or without HIV infection (aOR 0.78, 95% CI 0.46-1.32). In the PP analysis, the 99DOTS-based intervention increased the odds of treatment success (aOR 2.89, 95% CI 1.57-5.33, p = 0.001). The odds of completing the intensive phase of treatment and the odds of not being lost to follow-up were similarly improved in PP but not ITT analyses. Study limitations include the likelihood of selection bias in the PP analysis, inability to verify medication dosing in either arm, and incomplete implementation of some components of the intervention. CONCLUSIONS: 99DOTS-based treatment supervision did not improve treatment outcomes in the overall study population. However, similar treatment outcomes were achieved during the control and intervention periods, and those patients enrolled on 99DOTS achieved high treatment completion. 99DOTS-based treatment supervision could be a viable alternative to directly observed therapy for a substantial proportion of patients with TB. TRIAL REGISTRATION: Pan-African Clinical Trials Registry (PACTR201808609844917).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1003628

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Trial profile. ITT, intention-to-treat; PP, per protocol; TB, tuberculosis.
Fig 1 Trial profile. ITT, intention-to-treat; PP, per protocol; TB, tuberculosis.CC BY · PubMed Central
Fig 2 Adjusted proportions of treatment success. The data shown are adjusted proportions output by the primary analysis mixed effects logistic regression model for the (A) intention-to-treat analysis and (B) per protocol analysis.
Fig 2 Adjusted proportions of treatment success. The data shown are adjusted proportions output by the primary analysis mixed effects logistic regression model for the (A) intention-to-treat analysis and (B) per protocol analysis.CC BY · PubMed Central
Fig 3 Effectiveness of 99DOTS among subgroups. The data shown are odds ratios (ORs) from mixed effects logistic regression models for the (A) intention-to-treat analysis and (B) per protocol analysis. All models are adjusted for time (month), disease class (bacteriologically confirmed versus clinically diagnosed), and TB type (new versus retreatment) as fixed effects and site as a random effect. Sex-specific ORs are also adjusted for HIV status as a fixed effect, and HIV-status-specific ORs are also adjusted for sex as a fixed effect.
Fig 3 Effectiveness of 99DOTS among subgroups. The data shown are odds ratios (ORs) from mixed effects logistic regression models for the (A) intention-to-treat analysis and (B) per protocol analysis. All models are adjusted for time (month), disease class (bacteriologically confirmed versus clinically diagnosed), and TB type (new versus retreatment) as fixed effects and site as a random effect. Sex-specific ORs are also adjusted for HIV status as a fixed effect, and HIV-status-specific ORs are also adjusted for sex as a fixed effect.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 3

  1. World Health Organization, 2017, Global tuberculosis report 2017
  2. Everwell Health Solutions, 2021, 99DOTS: low-cost monitoring and improving medication adherence
  3. StataCorp, 2017, Stata statistical software. Release 15

Cited by

See all 88

Metadata

Authors
Cattamanchi, A., Crowder, R., Kityamuwesi, A., Kiwanuka, N., Lamunu, M., Namale, C., Tinka, L. K., Nakate, A. S., Ggita, J., Turimumahoro, P., Babirye, D., Oyuku, D., Berger, C., Tucker, A., Patel, D., Sammann, A., Turyahabwe, S., Dowdy, D., & Katamba, A.
Affiliations
  • San Francisco General Hospital (US)
  • Makerere University (UG)
  • Johns Hopkins University (US)
  • Ministry of Health (UG)
Corresponding author
Cattamanchi, Adithya
Venue
PLoS Medicine
Published
2021-05-06
Volume
18
Issue
5
Pages
e1003628
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W3157487954
Cited by
83
References
21
Citations by year
2026: 17 · 2025: 16 · 2024: 15 · 2023: 17 · 2022: 14 · 2021: 4
FWCI
3.96
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
The Stop TB Partnership (STBP/TBREACH/GSA/W6-37, (STBP/TBREACH/GSA/W6-37))
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Keywords
tuberculosis, digital adherence technologies, treatment supervision, treatment completion, drug-susceptible pulmonary tuberculosis, HIV coinfection, sex differences, Uganda, mobile health
MeSH terms
Assessment of Medication Adherence, Adult, Antitubercular Agents, Female, Humans, Male, Middle Aged, Technology, Tuberculosis, Pulmonary, Uganda, Cluster Analysis, Drug Monitoring, Medication Adherence, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda. https://app.cochat.ai/papers/10.1371/journal.pmed.1003628
The paper
Cattamanchi, A., Crowder, R., Kityamuwesi, A., Kiwanuka, N., Lamunu, M., Namale, C., Tinka, L. K., Nakate, A. S., Ggita, J., Turimumahoro, P., Babirye, D., Oyuku, D., Berger, C., Tucker, A., Patel, D., Sammann, A., Turyahabwe, S., Dowdy, D., & Katamba, A. (2021). Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda. PLoS Medicine. https://doi.org/10.1371/journal.pmed.1003628

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.